ZA200104815B - Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors. - Google Patents
Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors. Download PDFInfo
- Publication number
- ZA200104815B ZA200104815B ZA200104815A ZA200104815A ZA200104815B ZA 200104815 B ZA200104815 B ZA 200104815B ZA 200104815 A ZA200104815 A ZA 200104815A ZA 200104815 A ZA200104815 A ZA 200104815A ZA 200104815 B ZA200104815 B ZA 200104815B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- preparation
- nucleotide synthesis
- cancer
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 22
- 239000003112 inhibitor Substances 0.000 title claims description 22
- 239000002773 nucleotide Substances 0.000 title claims description 22
- 125000003729 nucleotide group Chemical group 0.000 title claims description 22
- 238000003786 synthesis reaction Methods 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 title claims description 8
- 230000001225 therapeutic effect Effects 0.000 title description 5
- 238000009472 formulation Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 67
- 238000002360 preparation method Methods 0.000 claims description 20
- 230000010235 enterohepatic circulation Effects 0.000 claims description 16
- 229920001268 Cholestyramine Polymers 0.000 claims description 14
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 claims description 14
- 230000009471 action Effects 0.000 claims description 14
- 229960001678 colestyramine Drugs 0.000 claims description 14
- 238000006073 displacement reaction Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229920002911 Colestipol Polymers 0.000 claims description 5
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 5
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 claims description 4
- 229950010231 brequinar Drugs 0.000 claims description 4
- 229960002604 colestipol Drugs 0.000 claims description 4
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229950000844 mizoribine Drugs 0.000 claims description 4
- -1 2- morpholinoethyl Chemical group 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims description 3
- MVCKCEDAMDIWAO-UHFFFAOYSA-N 2-cyano-n-(4-cyanophenyl)-3-cyclopropyl-3-hydroxyprop-2-enamide Chemical compound C=1C=C(C#N)C=CC=1NC(=O)C(C#N)=C(O)C1CC1 MVCKCEDAMDIWAO-UHFFFAOYSA-N 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000010453 lymph node cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 239000002213 purine nucleotide Substances 0.000 claims description 2
- 150000003212 purines Chemical class 0.000 claims description 2
- 239000002719 pyrimidine nucleotide Substances 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 2
- 229940045145 uridine Drugs 0.000 claims description 2
- QEQSEVUANZQWOT-UHFFFAOYSA-N 3-cyano-4-hydroxy-n-[4-(trifluoromethyl)phenyl]oct-3-en-7-ynamide Chemical compound C#CCCC(O)=C(C#N)CC(=O)NC1=CC=C(C(F)(F)F)C=C1 QEQSEVUANZQWOT-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000036765 blood level Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- VQMSRUREDGBWKT-UHFFFAOYSA-N cinchoninic acid Natural products C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 description 1
- 229940097479 colestid Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011549 displacement method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-O lysinium group Chemical class [NH3+][C@@H](CCCCN)C(=O)O KDXKERNSBIXSRK-YFKPBYRVSA-O 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MEZYCNMPBPQTLK-ONEGZZNKSA-N methyl (e)-hex-4-enoate Chemical compound COC(=O)CC\C=C\C MEZYCNMPBPQTLK-ONEGZZNKSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- FAGUFWYHJQFNRV-UHFFFAOYSA-N tetraethylenepentamine Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
) 1 20014815 ) Hoechst Marion Roussel Deutschland GmbH HMR 1998/L 080 Dr. TH/mk
Strongly basic anion exchangers are employed in therapy as hypolipidemics in heterozygous familial hypercholesterolemia and other primary hyperipoproteinemias having a principal proliferation of the LDL fraction or in chologenic diarrheas. Examples of suitable active substances which are employed as hypolipidemics are N-(2-aminoethyl)-N'- [2-[(2-aminoethyl)amino]ethyl]-1,2-ethanediamine polymers with (chioromethyl)oxirane, which is also called colestipol (Colestid®) or colestyramine (CAS-No. 11 041-12-6), which is a styrene/divinylbenzene copolymer. Isoxazole or crotonamide derivatives are described in the
Patent Applications EP 484 223; EP 529 500; US 4 061 767; EP 538 783 or EP 551 230. Compounds which inhibit purine or pyrimidine synthesis are called nucleotide synthesis inhibitors (Burkhardt and Kalden; Rheumat. Int. (1997); 17: 85-90), these are, for example, compounds of the formula and/or II, brequinar (6-fluoro-2-(2’-fluoro[1,1 biphenyl]-4-yl)-3-methyi- 4-quinolinecarboxylic acid), mycophenolatemofetil (2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5- yl)-4-methyl-4-hexenoate), methotrexate (CAS No. 59-05-02) or mizoribine (CAS No. 50924-49-7), are absorbed in the intestine of patients after oral administration and, after a brief increase in the blood levels after administration (absorption peak), lead to constant high blood levels. The abovementioned nucleotide synthesis inhibitors are excreted again in the intestine via the liver and the bile. The excreted compounds mentioned can partially be absorbed again from the intestine and secreted into the blood.
The compounds mentioned are therefore subject to the enterohepatic circulation. .
In the employment of nucleotide synthesis inhibitors for affecting the immune system, it was surprisingly found that only brief active effects of these substances are needed for the desired action on the immune system. ;
If blood levels of these substances which lead to active effects are maintained over a relatively long period, although the side effects increase, the desired action on the immune system is not increased. By limiting the active effects to a short period of time, the tolerability of a therapy can be improved while maintaining the desired pharmacodynamic effects on the immune system (=improved therapeutic breadth).
In the case of nucleotide synthesis inhibitors which are subject to the enterohepatic circulation, the duration of action can be reduced by administering substances which interrupt the enterohepatic circulation.
Owing to interruption of the enterohepatic circulation, the desired action on the immune system is maintained, but the side effects are drastically reduced.
The abovementioned nucleotide synthesis inhibitors can also have an improved therapeutic breadth in their action if compounds which antagonize the action of the nucleotide synthesis inhibitors are administered with a displacement in time — i.e. later than the nucleotide synthesis inhibitors.
The term therapeutic breadth is understood here as meaning a measure of the tolerability of a pharmaceutical and is essentially the difference between the lowest dose which still leads to the desired therapeutic effects and the dose which leads to side effects. The yardstick for the improvements achieved is, for example, the amount of red blood corpuscles, hemoglobin content, hematocrit, amount of glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, alkaline phosphatase (from bone marrow) or amylase and the weight in comparison with untreated patients.
The invention therefore relates to a preparation comprising 1) at least one compound which essentially prevents the enterohepatic circulation of the nucleotide synthesis inhibitors or antagonizes the action of the nucleotide synthesis inhibitors with a displacement in time, and . 2) at least one nucleotide synthesis inhibitor from the group consisting ) of brequinar, mycophenolatemofetil (2-Morpholinoethyl (E)-6-(1,3- "35 dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl}-4- ;
“UJ1d4810 methyl-4- hexenoate), methotrexate, mizoribine and compounds of the formulae | and Ii
I
TC c— fe R?
N. ° « X M
R3
Bi
NC—C—C— ne R2 ] X= ti) c Re yar and/or an optionally stereoisomeric form of the compound of the formula | or Il and/or a physiologically tolerable salt of the compound of the formula Il, where
R'is a) (C4-Cu)-alkyl, b) (C3-Cs)-cycloalkyl,
Cc) (Co-Ce)-alkenyl or d) (Cz-Ce)-alkynyl,
R%is a) -CFs, b) -O-CF3,
Cc) -S-CF3, d) -OH, e) -NO, f) halogen, g) benzyl, h) phenyl, i) -O-phenyl, k) -CN or 1) -O-phenyl, mono- or polysubstituted by 1) (C4-Cy)alkyl, 2) halogen, 3) -O-CF3 or 4) -O-CHs,
R%is a) (Cy-Cs)alkyl, b) halogen, or
} c) is a hydrogen atom, and
Xis a) a —CH group or b) a nitrogen atom.
A mixture of the nucleotide synthesis inhibitors and compounds of the formulae | and ll or salts of the compounds of the formula Il and a mixture of the compounds which essentially prevent the enterohepatic circulation of the compound of the formula | or Il can also be employed.
The term “compound which essentially prevents the enterohepatic circulation of the compound of the formula | or II” is understood as meaning, for example, strongly basic anion exchangers such as colestipol and colestyramine or active carbon. The term "compounds which antagonize the action of the nucleotide synthesis inhibitors with a displacement in time” are understood as meaning compounds such as uridine, purine, purine nucleotides or pyrimidine nucleotides.
The use of a compound of the formula | and/or ll and/or an optionally stereoisomeric form of the compound of the formula | or II and/or a salt of the compound of the formula Il is preferred, where,
R'is a) methyl, b) cyclopropyl or
Cc) (C3-Cs)-alkynyl,
R%is -CF3 or -CN,
R3is a hydrogen atom or methyl, and
Xis a —CH group, in combination with at least one compound from the group consisting of colestipol, colestyramine and active carbon.
The use of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide,
N-(4-trifluoromethyiphenyl)-2-cyano-3-hydroxycrotonamide, 2-cyano- 3-cyclopropyl-3-hydroxyacrylic acid (4-cyanophenyl)amide or - N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxyhept-2-en-6-ynecarbox- amide in combination with colestyramine is particularly preferred.
The compound of the formula | or Il is prepared according to known processes such as are described in EP 484 223; EP 529 500;
US 4 061 767; EP 538 783 or EP 551 230. The starting substances for the chemical reactions are known or can easily be prepared by methods which 5 are known from the literautre.
The terms alkyl, alkenyl and alkynyl are understood as meaning radicals whose carbon chain can be straight or branched. The alkenyl or alkynyl radicals can furthermore also contain a number of double bonds or a number of triple bonds. Cyclic alkyi radicals are, for example, 3- to 5-membered monocyclic systems such as cyclopropyl, cyclobutyl or cyclopentyl. Salts of the compound of the formula II are, for example, sodium or lysinium salts which can be prepared as described in European
Patent Application No. EP 0769296.
The preparation according to the invention is suitable, for example, for the treatment of - immunological disorders - inflammatory and cytotoxic processes in connection with gene therapy interventions - carcinomatous disorders such as lung cancer, leukemia, ovarian cancer, sarcoma, Kaposi's sarcoma, meningioma, intestinal cancer, lymph node cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer or skin cancer - autoimmune disorders such as systemic lupus erythematosus or multiple sclerosis - rheumatic disorders - transplantations or graft-versus-host reactions or host-versus-graft reactions - disorders which are caused by strongly proliferating cells - psoriasis or atypic dermatitis - allergy, asthma, urticaria, rhinitis or uveitis - type Il diabetes - cystic fibrosis, colitis, liver fibrosis or sepsis
- chronic inflammatory disorders such as arteriosclerosis, Crohn’s disease, ulcerative colitis.
The invention also relates to a process for the production of the preparation, which comprises bringing the nucleotide synthesis inhibitors and a compound which essentially prevents the enterohepatic circulation of the nucleotide synthesis inhibitors, or antagonizes the action of the nucleotide synthesis inhibitors with a displacement in time, into a suitable administration form with a pharmaceutically suitable and physiologically acceptable vehicle and, if appropriate, further suitable active compounds, additives or excipients.
The preparation according to the invention can also include compositions or combination packs in which the constituents are placed next to one another and can therefore be used simultaneously, separately or sequentially on one and the same human or animal body. The sequential administration of the compound of the formula | and/or [I before the administration of the compound which essentially prevents the enterohepatic circulation of the compound of the formula | or Il is preferred.
To this end, for example, N-(4-trifluoromethylphenyl)-2-cyano-3- hydroxycrotonamide (called compound 1 in the following) is administered first. Colestyramine, which essentially prevents the enterohepatic circulation of the compound |, is administered with a displacement in time, i.e., for example, 2 hours or 4 hours after the administration of compound 1.
Owing to this time-displaced administration of the compound 1 and colestyramine, the compound 1 is initially absorbed unhindered from the digestive tract. After the administration of colestyramine, which is not absorbed systemically, the compound 1 excreted via the bowel is bound to colestyramine and can therefore not be reabsorbed again; as a result an interruption to the enterohepatic circulation is brought about. Owing to this measure, the duration of action and the blood level of the compound 1 are drastically reduced. Despite this drastically reduced blood level, the activity in the pathological animal model, such as adjuvant arthritis, is not reduced by the administration of colestyramine at a low, still just active dose of "35 approximately 2.5 mg/kg/day of the compound 1. If high doses of
25 mg/kg/day of the compound 1, which already lead to various side effects, are employed in the same animal model, a clear reduction in the side effects with retention of the desired actions on the immune system is observed by means of administration of colestyramine.
The preparation according to the invention can be present as a dose unit in the form of pharmaceutical forms such as capsules (including microcapsules), which in general contain no pharmaceutical vehicles), tablets including coated tablets and pills, or suppositories, it being possible when using capsules for the capsule material to assume the function of the vehicle and for the contents to be present, for example, as a powder, gel, solution, emulsion or dispersion. It is particularly advantageous and simple, however, to prepare oral or peroral formulations which contain the calculated amounts of the active compounds together with any desired pharmaceutical vehicles using the two active compound components 1) (e.g. colestyramine) and 2) (compound of the formula | and/or ll). An appropriate formulation (suppositories) for rectal therapy can also be used.
Transdermal administration in the form of ointments or creams, parenteral (intraperitoneal, subcutaneous, intramuscular) injection or oral administration of solutions which contain the combinations according to the invention is likewise possible. In addition to the active compound, ointments, pastes, creams and powders can contain the customary vehicles, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, silicic acid, aluminum hydroxide, talc, zinc oxide, lactose, bentonites, calcium silicate and polyamide powder or mixtures of these substances. The tablets, pills or granule bodies can be produced by processes such as pressing, dipping or fluidized-bed processes or pan coating and contain vehicles and other customary excipients such as gelatin, agarose, starch (e.g. potato, con or wheat starch), celluloses such as ethylcellulose, silica, magnesium carbonate, various sugars such as lactose and/or calcium phosphates. The coating solution usually consists of sugar and/or starch syrup and mostly additionally contains gelatin, synthetic cellulose esters, gum arabic, polyvinylpyrrolidone, pigments, surface-active substances, plasticizers and similar additives according to the prior art. For the © 35 production of the preparation forms, any customary flow-regulating agent,
lubricant or glidant such as magnesium stearate and release agents can be used. The preparations preferably have the form of coating/core tablets or multilayer tablets, the active component 2 being in the coating or in the core or in one layer, while the active component 1 is in the core, in the coating or in another layer. The active compound components can also be present in delayed-release form or adsorbed on release-delaying material or included in the release-delaying material (e.g. those based on cellulose or polystyrene resins, e.g. hydroxyethylcellulose). Delayed release of the active compounds can also be achieved by providing the layer or the compartment concerned with customary enteric coatings.
A delayed release of the compound which essentially prevents the enterohepatic circulation of the compound of the formula | or Il is preferred.
The dose to be used is, of course, dependent on various factors such as the living being to be treated (i.e. human or animal), age, weight, general state of health, the degree of severity of the symptoms, the disorder to be treated, possible concomitant disorders (if present), the nature of the concomitant treatment with other pharmaceuticals, or the frequency of the treatment. The doses are in general administered several times per day and preferably one to three times per day. The amounts of individual active compound used are based here on the recommended daily dose of the respective individual active compound and, in the combination preparation, should in general be from 10% to 300% of the recommended daily dose, preferably from 50% to 150%, in particular 80%. Suitable therapy with the combinations according to the invention thus consists, for example, in the administration of 1, 2 or 3 individual doses of the preparation consisting of
N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide or
N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide in an amount of from 2 mg to 250 mg, preferably 5 mg to 150 mg, in particular 10 mg to 50 mg, particularly preferably 10 mg to 20 mg, and colestyramine in an amount of from 250 mg to 6000 mg, in particular from 1500 mg to 3000 mg.
The preparations according to the invention can furthermore aiso be employed together with other suitable active compounds, for example antiuricopathics, analgesics, steroidal or nonsteroidal antiinflammatories, © 35 platelet aggregation inhibitors, cytokines, cytokine agonists, cytokine antagonists or immunosuppressant compounds such as cyclosporin A, FK 506 or rapamycin.
Example 1
Adjuvant-induced arthritis, modification according to Perper (Proc. Soc. exp. Biol. Med. 137, 506 (1971))
The experimental animals used were male rats of a Lewis strain (Moellegard, Denmark) having a body weight of from 160 to 210 g. On the 1st day, the animals were injected subcutaneously, into the tail root, with complete Freund's adjuvant containing a mycobacterium butyricum suspension in heavy paraffin oil (Difco; 6 mg/kg in paraffin oil; Merck). The compounds N-(4-trifluoromethylphenyli}-2-cyano-3-hydroxycrotonamide and colestyramine were suspended in carboxymethyicellulose (1% in water) and administered orally. The compounds were administered once daily from the 1st to the 17th day of the experiment; the paw volume and arthritis index were then determined on the 18th day.
The severity of the disorder was determined by measuring the paw volume of both hind paws. The measurement was carried out by means of the water displacement method using a 2060 Plethys monitor (Rhema-
Labortechnik, Hofheim, Germany). The arthritis index was furthermore determined in the 18th day after injection.
Determination of the arthritis index: 1. ears 0.5 points for each ear on which reddening occurs and nodules are formed 2.nose 1 point for connective tissue swelling 3. tail 1 point for the emergence of nodules 4. fore paws 0.5 points for each paw on which at least one inflammation occurs on a joint 5. hind paws 1 point for slight inflammation (swelling) 2 points for a medium-strength inflammation 3 points for a masive inflammatory reaction . On the 1st day, animals of an “arthritis contro” control group were given a subcutaneous injection, into the tail root, with complete Freund's adjuvant and were given, however, only the solvent (1% carboxymethylcellulose in +35 water). 6 animals in each case were used per dose and in the control
Claims (10)
1. A preparation comprising 1) at least one compound which essentially prevents the enterohepatic circulation of the nucleotide synthesis inhibitors or antagonizes the action of the nucleotide synthesis inhibitors with a displacement in time, and 2) at least one nucleotide synthesis inhibitor from the group consisting of brequinar, mycophenolatemofetile (2- morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxoisobenzofuran-5-yi}-4-methyl-4- hexenoate), methotrexate, mizoribine and compounds of the formulae and Il I NT c— ne R2
N. o “ X ( R3 I NC—C—C— ne R2 I X= c Re (mn ar and/or an optionally sterecisomeric form of the compound of the formula | or Il and/or a physiologically tolerable salt of the compound of the formula Il, where R'is a) (C1-Cs)-alkyl, b) (C3-Cs)-cycloalkyl, Cc) (C2-Cs)-alkenyi or d) (C2-Cg)-alkynyl, R%is a) -CFs, b) -O-CF3, c) -S-CF3, d) -OH, e) -NO,, f) halogen, g) benzyl,
h) phenyl, i) -O-phenyl, k) -CN or )) -O-phenyl, mono- or polysubstituted by 1) (C+-Ca)-alkyl, 2) halogen, 3) -O-CF; or 4) -O-CHa, Ris a) (C4-Cu)alkyl, b) halogen, or Cc) is a hydrogen atom, and Xis a) a —CH group or Cc) a nitrogen atom.
2. A preparation as claimed in claim 1, where a compound of the formula | and/or Il and/or an optionally stereoisomeric form of the compound of the formula | or Il and/or a salt of the compound of the formula Il is employed, where R'is a) methyl, b) cyclopropyl or c) (C3-Cs)-alkynyl, R? is -CF3 or -CN, R3 is a hydrogen atom or methyl, and Xis a —CH group.
3. A preparation as claimed in claim 1 or 2, where N-(4-trifluoromethyl- phenyl )-5-methylisoxazole-4-carboxamide is employed as a compound of the formula | or N-(4-trifluoromethylphenyl)-2-cyano- 3-hydroxycrotonamide, 2-cyano-3-cyclopropyl-3-hydroxyacrylic acid (4-cyanophenyl)amide or N-(4-trifluoromethylphenyl)-2-cyano-3- hydroxyhept-2-en-6-ynecarboxamide is employed as compound of the formula Il. .
4, A preparation as claimed in one or more of claims 1 to 3, wherein "35 the compound employed which essentially prevents the enterohepatic circulation of the compound of the formula I or Il is a compound from the group consisting of colestipol, colestyramine and active carbon.
65. A preparation according to one or more of claims 1 to 3, wherein the compound employed which antagonizes the action of the nucleotide synthesis inhibitors with a displacement in time is a compound from the group consisting of uridine, purine, purine nucleotides or pyrimidine nucleotides.
6. A preparation as claimed in one or more of claims 1 to 5, wherein additional active compounds from the group consisting of antiuricopathics, analgesics, steroidal or nonsteroidal antiinflammatories, cytokines, cytokine agonists, platelet aggregation inhibitors, cytokine antagonists or immunosuppressant compounds such as cyclosporin A, FK 506 or rapamycin are contained.
7. A preparation as claimed in one or more of claims 1 to 6, which consists of compositions or combination packs in which the constituents are placed next to one another and are therefore used simultaneously, separately or sequentially on one and the same human or animal body.
8. A preparation as claimed in claim 7, wherein the administration of the compound of the formula | and/or Il is carried out timewise before the administration of the compound which essentially prevents the enterohepatic circulation of the compound of the formula | or Il.
9. The use of the preparation as claimed in one or more of claims 1 to 8 for the production of a pharmaceutical for treating immunological disorders, inflammatory and cytotoxic processes in connection with gene therapy interventions, carcinomatous disorders such as lung ) cancer, leukemia, ovarian cancer, sarcoma, Kaposi's sarcoma,
meningioma, intestinal cancer, lymph node cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer or skin cancer, autoimmune disorders such as systemic lupus erythematosus or multiple sclerosis, rheumatic disorders, transplantations or graft-versus-host reactions or host-versus-graft reactions, disorders which are caused by strongly proliferating cells, psoriasis or atypic dermatitis, allergy, asthma, urticaria, rhinitis or uveitis, type Il diabetes, cystic fibrosis, colitis, liver fibrosis or sepsis, chronic inflammatory disorders such as arteriosclerosis, Crohn's disease or ulcerative colitis.
10. A process for the production of the preparation as claimed in claims 1 to 8, which comprises bringing at least one nucleotide synthesis inhibitor from the group consisting of brequinar, mycophenolatemofetil (2-morpholinoethyl (E)-6-(1,3-dihydro-4- hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl)4-methyl-4- hexenoate), methotrexate, mizoribine and compounds of the formulae | and Il and a compound which essentially prevents the . enterohepatic circulation of the compound of the formula | or ll, or a compound which antagonizes the action of at least one of the nucleotide synthesis inhibitors with a displacement in time into a suitable administration form with a pharmaceutically suitable and physiologically acceptable vehicle, and, if appropriate, further suitable active compounds, additives or excipients.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19857009A DE19857009A1 (en) | 1998-12-10 | 1998-12-10 | Preparation with improved therapeutic range, containing nucleotide synthesis inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200104815B true ZA200104815B (en) | 2002-06-13 |
Family
ID=7890633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200104815A ZA200104815B (en) | 1998-12-10 | 2001-06-13 | Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors. |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP1137438B1 (en) |
JP (1) | JP2002531525A (en) |
KR (1) | KR20010080729A (en) |
CN (1) | CN1189214C (en) |
AR (1) | AR021577A1 (en) |
AT (1) | ATE218370T1 (en) |
AU (1) | AU766810B2 (en) |
BG (1) | BG105548A (en) |
BR (1) | BR9916006A (en) |
CA (1) | CA2354266A1 (en) |
CZ (1) | CZ20012029A3 (en) |
DE (2) | DE19857009A1 (en) |
DK (1) | DK1137438T3 (en) |
EA (1) | EA005136B1 (en) |
EE (1) | EE200100305A (en) |
ES (1) | ES2178496T3 (en) |
HK (1) | HK1041598B (en) |
HR (1) | HRP20010429A2 (en) |
HU (1) | HUP0104624A3 (en) |
IL (1) | IL143586A0 (en) |
MX (1) | MXPA01005861A (en) |
NO (1) | NO20012719L (en) |
NZ (1) | NZ511882A (en) |
PL (1) | PL349336A1 (en) |
PT (1) | PT1137438E (en) |
SI (1) | SI1137438T1 (en) |
SK (1) | SK284842B6 (en) |
WO (1) | WO2000033876A1 (en) |
YU (1) | YU39901A (en) |
ZA (1) | ZA200104815B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072527A2 (en) * | 2001-03-13 | 2002-09-19 | Protagen Aktiengesellschaft | 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
DE10112924A1 (en) * | 2001-03-13 | 2002-10-02 | Erich Eigenbrodt | 1-butanoic acid derivatives, pharmaceutical compositions containing such derivatives and uses of such derivatives |
GB0123571D0 (en) | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
WO2004012746A2 (en) * | 2002-08-02 | 2004-02-12 | The Regents Of The University Of California | New uses for inhibitors of inosine monophosphate dehydrogenase |
JP2005538165A (en) * | 2002-09-06 | 2005-12-15 | シェボ ビオテック アクティエン ゲゼルシャフト | Compound for regulating glycolytic enzyme and / or aminotransferase complex |
JPWO2005060980A1 (en) * | 2003-12-24 | 2007-12-13 | 正彬 少名子 | Drugs for treating diseases and drugs for treating diabetes |
DE102005017592A1 (en) * | 2005-04-16 | 2006-10-19 | Lindner, Jürgen, Dr. med. | Dosage forms and combination preparations of pyrimidine biosynthesis inhibitors to achieve additional effects on the immune system |
MX2009011816A (en) | 2007-05-03 | 2009-11-19 | Pfizer Ltd | 2 -pyridine carboxamide derivatives as sodium channel modulators. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4127737A1 (en) * | 1991-08-22 | 1993-02-25 | Hoechst Ag | MEDICINAL PRODUCTS FOR TREATMENT OF REPELLATION REACTIONS IN ORGAN PLANTING |
ES2079765T3 (en) * | 1991-10-23 | 1996-01-16 | Hoechst Ag | DERIVATIVES OF N-PHENYL-2-CIANE-3-HYDROXICROTONIC ACID AMIDES AND THEIR USE AS A MEDICINE WITH IMMUNOMODULATING PROPERTY. |
IT1254519B (en) * | 1992-03-16 | 1995-09-25 | Chiesi Farma Spa | ASSOCIATIONS OF ANTIVIRAL COMPOUNDS |
DE19539638A1 (en) * | 1995-10-25 | 1997-04-30 | Hoechst Ag | The use of isoxazole and crotonic acid amide derivatives for the treatment of cancer |
AU4596097A (en) * | 1996-09-26 | 1998-04-17 | Williams, James W. | Improved therapeutic uses of 4-quinoline-carboxylic acid derivatives |
-
1998
- 1998-12-10 DE DE19857009A patent/DE19857009A1/en not_active Withdrawn
-
1999
- 1999-12-01 BR BR9916006-4A patent/BR9916006A/en not_active IP Right Cessation
- 1999-12-01 HU HU0104624A patent/HUP0104624A3/en unknown
- 1999-12-01 ES ES99961041T patent/ES2178496T3/en not_active Expired - Lifetime
- 1999-12-01 IL IL14358699A patent/IL143586A0/en unknown
- 1999-12-01 SI SI9930063T patent/SI1137438T1/en unknown
- 1999-12-01 WO PCT/EP1999/009380 patent/WO2000033876A1/en not_active Application Discontinuation
- 1999-12-01 AU AU17793/00A patent/AU766810B2/en not_active Ceased
- 1999-12-01 YU YU39901A patent/YU39901A/en unknown
- 1999-12-01 CZ CZ20012029A patent/CZ20012029A3/en unknown
- 1999-12-01 AT AT99961041T patent/ATE218370T1/en not_active IP Right Cessation
- 1999-12-01 DE DE59901681T patent/DE59901681D1/en not_active Expired - Fee Related
- 1999-12-01 PT PT99961041T patent/PT1137438E/en unknown
- 1999-12-01 DK DK99961041T patent/DK1137438T3/en active
- 1999-12-01 NZ NZ511882A patent/NZ511882A/en unknown
- 1999-12-01 KR KR1020017007176A patent/KR20010080729A/en not_active Application Discontinuation
- 1999-12-01 SK SK788-2001A patent/SK284842B6/en unknown
- 1999-12-01 EA EA200100647A patent/EA005136B1/en not_active IP Right Cessation
- 1999-12-01 CA CA002354266A patent/CA2354266A1/en not_active Abandoned
- 1999-12-01 CN CNB998142433A patent/CN1189214C/en not_active Expired - Fee Related
- 1999-12-01 JP JP2000586366A patent/JP2002531525A/en not_active Withdrawn
- 1999-12-01 EE EEP200100305A patent/EE200100305A/en unknown
- 1999-12-01 MX MXPA01005861A patent/MXPA01005861A/en active IP Right Grant
- 1999-12-01 EP EP99961041A patent/EP1137438B1/en not_active Expired - Lifetime
- 1999-12-01 PL PL99349336A patent/PL349336A1/en not_active Application Discontinuation
- 1999-12-07 AR ARP990106239A patent/AR021577A1/en not_active Application Discontinuation
-
2001
- 2001-05-30 BG BG105548A patent/BG105548A/en unknown
- 2001-06-01 NO NO20012719A patent/NO20012719L/en not_active Application Discontinuation
- 2001-06-07 HR HR20010429A patent/HRP20010429A2/en not_active Application Discontinuation
- 2001-06-13 ZA ZA200104815A patent/ZA200104815B/en unknown
-
2002
- 2002-05-02 HK HK02103282.9A patent/HK1041598B/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100464693B1 (en) | Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonic acid amide | |
JP2001519391A (en) | New combinations | |
IE61232B1 (en) | Medicaments to combat chronic graft-versus-host diseases and to combat autoimmune diseases, in particular systemic lupus erythematosus | |
JPH11349482A (en) | Medicament | |
ZA200104815B (en) | Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors. | |
US20050255071A1 (en) | Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors | |
CA1069441A (en) | Pharmaceutical composition containing 2,1,3-benzothiazole | |
EP0787491B1 (en) | Preventive and remedy for type i allergic diseases | |
JPH0140009B2 (en) | ||
AU702727B2 (en) | Arteriosclerosis depressant | |
AU718237B2 (en) | Use of xanthine derivatives for the modulation of apoptosis | |
US4315934A (en) | Organic compounds | |
JP2001510155A (en) | Treatment and prevention of cardiac disorders using selective serotonin reuptake inhibitors | |
JP2004051639A (en) | Medicinal composition for treating arteriosclerosis | |
US4152435A (en) | Compositions and methods to treat hypertension comprising a pyridazine and N-amidino-2-(2,6-dichlorophenyl) acetamide | |
KR20040032969A (en) | Medicinal compositions containing angiotensin ii receptor antagonist | |
WO1999055157A1 (en) | R-rabeprazole compositions and methods | |
JPS6323969B2 (en) | ||
MXPA98007564A (en) | Preparation in combination containing 5-methyl-4'-trifluometil-4'-isoxazolcarboxanilide and n- (4-trifluorometilfenil) -2-cyano-3-hydroxicrotonam | |
NZ332627A (en) | Use of substituted azaspirane in the treatment of asthma |